Dr. Reddy's Laboratories' (NSE:DRREDDY) consolidated attributable profit plunged to 2.21 billion Indian rupees in the fiscal fourth quarter ended March 31, from 15.9 billion rupees a year ago.
Earnings per share contracted to 2.64 rupees from 19.11 rupees a year earlier, the pharmaceutical company said in a filing to the Indian stock exchanges on Tuesday. The EPS was much lower than the 10.45 rupees estimated by the analysts polled by Visible Alpha.
Revenue in fiscal Q4 also slipped to 75.2 billion rupees from 85.1 billion rupees a year ago. This was also lower than Visible Alpha's estimate of 81.6 billion rupees.
The company's board recommended a final dividend of 8 rupees per equity share of face value of 1 rupee each for the financial year 2025-26. The record date to determine the members eligible to receive the dividend has been fixed as July 10.